BRCA2 and cancer: Further work is required to determine if BRCA1 and BRCA2 are potential intermediate biomarkers that predict the efficacy of these or other prevention agents and whether a combination of I3C and genistein can provide greater cancer prevention efficacy with the same or less toxicity (i.e., a better therapeutic ratio).